Galsulfase Iv Suppliers & Bulk Manufacturers
Available Forms: Lyophilized powder for IV
Available Strengths: 1mg/ml
Reference Brands: Vimizim®(US & EU)
Category:
Orphan Drugs
Galsulfase is an enzyme replacement therapy that provides the deficient N-acetylgalactosamine-6-sulfatase enzyme in Morquio A syndrome. It reduces the buildup of glycosaminoglycans in the body, improving mobility, breathing, and overall functioning, leading to enhanced quality of life in affected patients.
Product Description:
Galsulfase, marketed as Vimizim®, is approved in the US and EU for mucopolysaccharidosis type IVA (Morquio A syndrome). Regulatory dossiers include comprehensive clinical trial data, manufacturing practices, and safety profiles submitted to FDA and EMA, supporting its approval. Dossiers demonstrate its efficacy in reducing symptoms and improving mobility. Administered via IV infusion, dosing is individualized according to patient weight. For in-depth insights on regulatory submissions, dossier requirements, and market approvals, visit PharmaTradz, your trusted source for pharmaceutical regulatory updates and industry insights.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing